Raptor Pharmaceuticals Corp.
(NASDAQ : RPTP)

( )
RPTP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.99%156.120.7%$1151.45m
PFEPfizer Inc. 0.50%34.370.9%$1063.61m
MRKMerck & Co., Inc. 1.34%73.140.7%$859.53m
BMYBristol-Myers Squibb Co. 1.75%60.381.0%$833.94m
ABBVAbbVie, Inc. 0.99%106.701.9%$716.41m
LLYEli Lilly & Co. 3.13%206.811.1%$635.54m
AZNAstraZeneca Plc 1.76%48.061.2%$486.33m
GSKGlaxoSmithKline Plc 1.84%34.910.2%$272.42m
NVSNovartis AG 0.64%84.030.2%$166.37m
SNYSanofi 1.50%46.590.2%$163.16m
VTRSViatris, Inc. 2.36%13.910.0%$134.52m
VERUVeru, Inc. 1.15%12.330.0%$121.05m
KALVKalVista Pharmaceuticals, Inc. -2.16%30.880.4%$99.62m
NVONovo Nordisk A/S 0.58%69.620.1%$91.37m
CVACCureVac NV 1.67%82.690.0%$80.07m

Company Profile

The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007.